Evidence map›Paper›PMID 26104898›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2015

[Research Progress of Biomakers Proteomics-based in Lung Cancer].

Hui Xie, Zhengang Chen, Guangshun Wang

Abstract readEnglish AbstractReview
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hui XieBaodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Zhengang ChenBaodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.
Guangshun WangBaodi Clinical Hospital, Tianjin Medical University, Tianjin 301800, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteomic technologies can be applied to cancer research to detect differential protein expression that could find cancer biomakers. Lung cancer biomarker discovery is significant due to its anticipated critical role in early diagnosis, therapy guidance, and prognosis monitoring of lung cancer. Therefore, there is an indeed need to identify new biomarkers for early diagnosis and prognosis that could serve to open novel therapeutic means. This article briefly introduces the latest reports in proteomic studies of lung cancer. It contains diagnostic, prognostic, and predictive biomarkers, and a summary based on the most recent literature and our own work.

Indexed as

Biomarkers, TumorHumansLung NeoplasmsProteomicsBiomarkers, Tumor

Identifiers

PMID26104898
PMCPMC5999909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.